Sign in

CIK 0001737287

  • Non-accelerated filer
  • Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
823562771
Phone
+1 650-457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale Director sold 10,000 shares at $11.76 ($117,600)
  2. 4 Open-market sale EVP of R&D and CMO sold 2,000 shares at $11.18 ($22,360)
  3. 4 Grant or award Director acquired 44,178 shares (grant or award)
  4. 4 Grant or award Director acquired 22,089 shares (grant or award)
  5. 4 Grant or award Director acquired 44,178 shares (grant or award)
  6. 4 Grant or award Director acquired 22,089 shares (grant or award)
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Open-market sale EVP of R&D and CMO sold 11,500 shares at $7.40 ($85,092)
  10. 4 Other disposition 10% owner disposed of 22,032,040 shares (other)
  11. 4/A Other disposition Director disposed of 4,710,120 shares (other)
  12. 4 Other disposition Director disposed of 4,710,121 shares (other)
  13. 4 Grant or award EVP of R&D and CMO acquired 237,358 shares (grant or award)
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Grant or award Chief Financial Officer acquired 237,358 shares (grant or award)
  18. 4 Grant or award General Counsel acquired 175,438 shares (grant or award)
  19. 4 Open-market sale EVP of R&D and CMO sold 5,169 shares at $7.71 ($39,848)
  20. 4 Open-market sale General Counsel sold 8,849 shares at $7.68 ($67,962)

Page 7 of 14 · 275 filings